Boston Scientific announced a definitive agreement to acquire Penumbra in a cash and stock transaction valuing the company at approximately $14.5 billion. The acquisition positions Boston Scientific to expand into fast growing vascular and neurovascular segments as cardiovascular disease prevalence rises globally. Penumbra has built a portfolio of mechanical thrombectomy and embolization devices used to treat pulmonary embolism stroke deep vein thrombosis acute limb ischemia and aneurysms across hospital settings worldwide serving clinicians with minimally invasive options for complex cases.
Under the agreement Penumbra shareholders may receive cash or Boston Scientific shares with the consideration split primarily toward cash financing through debt and existing liquidity. The transaction is expected to close in 2026 pending regulatory and shareholder approvals. Penumbra reported strong revenue growth and continues multi year research programs across vascular and neurovascular care. Boston Scientific expects near term earnings dilution followed by increasing accretion as integration progresses. The deal reflects continued consolidation as large device makers seek scale innovation and broader physician reach in high growth interventional markets while expanding global access to clot removal and embolization technologies addressing rising cardiovascular burden and supporting procedural efficiency across diverse healthcare systems worldwide for patients providers and payers over time globally.
Why it matters
The acquisition strengthens Boston Scientific’s position in high growth vascular therapies as demand rises for minimally invasive clot management technologies.
Source Attribution
Source: Boston Scientific
